American Heart Association Scientific Sessions 2017
More poster news: Patient-reported barriers to use of PCSK9 inhibitors
Results from this web-based US survey show that cost was the main reason given by patients for low initial and ongoing use of PCSK9 inhibitors. This survey was completed by 769 patients who signed up for a pharmaceutical company-sponsored patient support program after prescription for…
read more »
More poster news: Adherence to PCSK9 inhibitor therapy
In the ODYSSEY Open-Label Extension Study, adherence to continuation of alirocumab treatment was not an issue. The ODYSSEY Open-Label Extension Study included patients with heterozygous familial hypercholesterolemia (FH, inherited high cholesterol) after completion of 4 Phase 3 placebo-controlled studies (FH I, FH II, LONG TERM,…
read more »
More real-world experience with PCSK9 inhibitors
In this report from Charité Berlin, PCSK9 inhibitor therapy was effective in 499 patients with high and very high cardiovascular risk and substantial LDL cholesterol burden. Patients were either unable to attain guideline defined LDL cholesterol goal with maximally tolerated lipid lowering therapy or were…
read more »
GLAGOV diabetes analysis: atheroma regression with evolocumab similar to nondiabetics
Treatment with evolocumab resulted in comparable regression of coronary atherosclerosis in statin-treated patients with and without diabetes, reinforcing the need for intensive lipid lowering in diabetes patients. GLAGOV (GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound) compared the effects…
read more »
SPIRE FH Analysis: PCSK9 inhibition reduces cardiovascular events in FH patients
Statin-treated patients with familial hypercholesterolaemia (FH, inherited high cholesterol) derive a similar reduction in cardiovascular events with the PCSK9 inhibitor bococizumab as patients without FH, according to this analysis of data from six SPIRE studies. Outcomes trials in FH patients in the modern era of…
read more »
AHA Scientific Sessions 2017: More insights from FOURIER into very high-risk patients: PAD and high-risk MI
New analyses from FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) reinforce the very high risk of cardiovascular events in patients with peripheral arterial disease (PAD), recurrent myocardial infarction (MI) and multivessel disease. In patients with PAD, evolocumab on top…
read more »
